Ko KJ, Choo MS, Chang YS, et al. - This study was undertaken to evaluate the satisfaction and efficacy of mirabegron in patients with overactive bladder (OAB) symptoms who were unsatisfied with previous antimuscarinic treatment. Researchers conducted a 12‐week, open‐label study including adults with OAB who had been treated with antimuscarinics within 2 years of screening and expressed dissatisfaction over poor efficacy or adverse events of antimuscarinics. The primary endpoint included the percentage of patients reporting treatment satisfaction questions (TSQ) at week 12 (“very satisfied” or “somewhat satisfied”). Individuals were evaluated for willingness to continue treatment at 12‐weeks. The data exhibited that in patients with OAB, mirabegron improved the rates of treatment satisfaction and symptoms who were unsatisfied with prior antimuscarinic treatment.